業績

{ 111件 }

アメリカ内分泌学会(ENDO 2023Outstanding Abstract Award 桑原 咲先生

  • 2023
  • 糖尿病・内分泌グループ
  • 受賞

Aika Miya, Akinobu Nakamura, Yuka Suzuki, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Yoichi M. Ito, So Nagai, Hideaki Miyoshi, Tatsuya Atsumi Inverse association between glucose variability and body fat in type 2 diabetes with impaired endogenous insulin secretion using continuous glucose monitoring: a prospective observational study Diabetes, Obesity and Metabolism, in press

IF: 6.408

  • 2023
  • 糖尿病・内分泌グループ
  • 欧文論文/原著

Nomoto H.

Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes World J Diabetes

IF:4.560

  • 2023
  • 糖尿病・内分泌グループ
  • 欧文論文/総説

Takako Araki, Hiraku Kameda, Masaaki Yamamoto, Toru Tateno, Yasumasa Iwasaki, Run Yu, Constance Chik, Hiba Hashmi, Angela Radulescu, Lynn A Burmeister, Hidenori Fukuoka The impact of multi-cultural interfacility video case conference A novel education model after the COVID pandemic Journal of the Endocrine Society, in press.

IF:なし

  • 2023
  • 糖尿病・内分泌グループ
  • 欧文論文/原著

Takahashi Y, Nomoto H*, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, Cho KY, Miya A, Kameda H, Takeuchi J, Taneda S, Kurihara Y, Atsumi T, Nakamura A, Miyoshi H*.

Improvement of glycemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicenter, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1

study)

Diabetes Obes Metab, in press

IF = 6.408

  • 2023
  • 糖尿病・内分泌グループ
  • 欧文論文/原著

Miyoshi H, Matsuhisa M, Yabe D, Takahashi Y, Morimoto Y, Terauchi Y.

Use of iGlarLixi for the management of type 2 diabetes in Japanese clinical practice: prior treatment subgroup analysis of the SPARTA Japan study.

Diabetes Ther. 2023 in press

IF = 3.605

  • 2023
  • 糖尿病・内分泌グループ
  • 欧文論文/原著

Oe Y, Nomoto H, Nakamura A, Kuwabara S, Takahashi Y, Yasui A, Izumihara R, Miya A, Kameda H, Cho KY, Atsumi T, Miyoshi H.

Effect of beta-cell function on glucose variability when switching from insulin degludec plus a dipeptidyl peptidase-4 inhibitor to insulin degludec/liraglutide: preliminary results from a pilot study Int J Endocrinol, in press.

IF:2.803

  • 2023
  • 糖尿病・内分泌グループ
  • 欧文論文/原著

Nomoto H, Takahashi A, Nakamura A, Kurihara H, Takeuchi J, Nagai S, Taneda S, Kameda H, Miya A, Cho KY, Miyoshi H, Atsumi T.

Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl

peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study) BMJ Open Diab. Res. Care., in press

IF: 4.179、5-year IF4.270

  • 2022
  • 糖尿病・内分泌グループ
  • 欧文論文/原著

65回日本甲状腺学会学術集会 研修医・大学院生トラベルグラント 大江 悠希先生

  • 2022
  • 糖尿病・内分泌グループ
  • 受賞

Yuki Oe, Hiroshi Nomoto*, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Akinobu Nakamura, Hideaki Miyoshi, Tatsuya Atsumi.

Letter to the Editor regarding Efficacy of IDegLira versus IDegAsp therapy in patients with type 2 diabetes: A randomized crossover study by isCGM

Adv Ther, in press

IF: 4.070、5-year IF4.549

  • 2022
  • 糖尿病・内分泌グループ
  • 欧文論文/letter